Pathovacs Inc.

Ames, IA

UEI
GAEYBFGAB1N9
CAGE
5SAC3
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Minority Owned Business
  • For Profit Organization
  • Subcontinent Asian (Asian-Indian) American Owned
  • Subchapter S Corporation
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
Roy J. Carver Co-Lab, 1111 Woi Rd, Ames, IA 50011, USA
Website
pathovacs.com
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Biotechnology
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract awards

Award Agency Obligated Awarded
Pathovacs, INC. Will develop a prototype in vitro diagnostic device for qualitative screening of individuals for… 75N91022C00027 National Cancer Institute (NIH) $393,833
Sttr phase II W911QY20C0114 ACC Aberdeen Proving Ground $975,606
Sttr phase I W911QY18P0315 ACC Aberdeen Proving Ground $149,504
Analysis of biomarkers for identification of novel protein expression after traumatic brain injury. VA26312P1112 Veterans Integrated Service Network 23 (VHA) $7,500

Grant awards

Award Agency Obligated Awarded
Awards issued prior to january 20, 2025, were funded under previous administrations and may not reflect the… 20223361037856 Institute of Food Production and Sustainability (NIFA) $650,000
Broadly protective porcine streptococcus suis vaccines 20183361028500 National Institute of Food and Agriculture $99,546
Immunologically cross reactive proteins for broadly protective campylobacter chicken vaccines 201233610195011 National Institute of Food and Agriculture $99,750

Similar vendors

Vendor Location Primary NAICS
Biological Mimetics, Inc. UEI LJARDLY9MMK5 Frederick, MD 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Applied Biotechnology Institute Inc. UEI XNMLFC55AWN3 San Luis Obispo, CA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Aahi UEI EMQ1ANLATYS6 Seattle, WA 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Bavarian Nordic A / S UEI D2WABKK2LYX4 Hellerup 325414 Biological Product (except Diagnostic) Manufacturing
Solaris Vaccines, Inc. UEI G1P5NEDCERA9 Fort Collins, CO 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Pathovacs, Inc. is a biotechnology company based in Ames, Iowa, with a mission to develop new and effective universal protein subunit vaccines for infectious agents that are a major public health concern worldwide. The company specializes in creating novel vaccines and diagnostic technologies for use in both humans and animals.

Through federal contracts, Pathovacs has been awarded funding from agencies like the National Institutes of Health (NIH) and the Department of the Army. The NIH contract involved developing a prototype diagnostic device for rapid screening of hepatitis C virus antibodies, further advancing cancer and infectious disease research goals. The Army contract provided funding for the company's STTR Phase II research into chemical and biological defense technologies. These awards were set aside for small businesses and supported Pathovacs' research and development efforts. Additionally, the Army contract was a firm fixed price definitive contract with a performance period spanning multiple years.

In the realm of federal grants, Pathovacs received a two-year Project Grant from the United States Department of Agriculture's National Institute of Food and Agriculture. This SBIR/STTR Program funding supported the development of broadly protective porcine Streptococcus suis vaccines to safeguard the pork industry from losses associated with this bacterial pathogen. Pathovacs' work under this grant aimed to deliver new vaccine candidates with enhanced protection against various Streptococcus suis strains impacting swine health. The grant funding enabled the company to further its innovative research in developing effective vaccines for agricultural applications.

SBA capabilities narrative

From the vendor's SBA profile

Contract antigen discovery

Quick answers

Is Pathovacs Inc. registered in SAM.gov?

Yes. Pathovacs Inc.'s SAM.gov registration is active through February 11, 2027.

What is Pathovacs Inc.'s CAGE code?

Pathovacs Inc.'s CAGE code is 5SAC3, and its Unique Entity ID (UEI) is GAEYBFGAB1N9.

What is Pathovacs Inc.'s most recent federal award?

Pathovacs Inc.'s most recent federal contract award is Pathovacs, INC. Will develop a prototype in vitro diagnostic device for qualitative screening of individuals for… (75N91022C00027), from National Cancer Institute (NIH), on September 20, 2022.

On GovTribe

See Pathovacs Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login

Find teaming partners on GovTribe